Loading
A phase 1/2 trial of FWD1802 in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.
A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. is a phase 1/2 interventional study registered as NCT06064812 by Forward Pharmaceuticals Co., Ltd., with 99 participants planned, started 2023-09-12 and due to reach its primary completion in 2026-03. Interventions recorded: FWD1802.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Forward Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/